MSA
IONS icon

Marino Stram & Associates’s Ionis Pharmaceuticals IONS Stock Holding History

Marino Stram & Associates’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-500
Closed -$41K – 316
2019
Q1 		$41K Hold
500
– – 0.03% 179
2018
Q4 		$27K Hold
500
– – 0.02% 191
2018
Q3 		$26K Hold
500
– – 0.02% 219
2018
Q2 		$21K Hold
500
– – 0.02% 240
2018
Q1 		$22K Hold
500
– – 0.02% 242
2017
Q4 		$25K Buy
+500
New +$27.4K 0.02% 233

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marino Stram & Associates's IONS Position: Q2 2019 in Review

Marino Stram & Associates sold out of Ionis Pharmaceuticals (IONS) in Q2 2019, closing a stake of 500 shares — an estimated $41K sold.

Marino Stram & Associates first reported a position in IONS in Q4 2017 and held it in 6 quarters. The position peaked at $41K in Q1 2019. 396 funds tracked by Wall St. Rank hold IONS as of Q2 2019.

  • Marino Stram & Associates reported no remaining Ionis Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Marino Stram & Associates sold 500 Ionis Pharmaceuticals shares in Q2 2019, an estimated $41K.
  • Marino Stram & Associates first reported a position in Ionis Pharmaceuticals in Q4 2017 and held it in 6 quarters.
  • Marino Stram & Associates's Ionis Pharmaceuticals position peaked at $41K in Q1 2019.
  • 396 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2019.

Based on Marino Stram & Associates's 13F filing for Q2 2019, filed 19 Jul 2019.